Trofinetide NNZ-2566 CAS: 853400-76-7

CAS NO: 853400-76-7
Trofinetide NNZ-2566
Chemical Name: Trofinetide
Molecular Formula: C13H21N3O6
Formula Weight: 315.32
CAS No.: 853400-76-7
Description Review
Description

Trofinetide NNZ-2566 is a promising medical product that has garnered significant interest from both the medical community and the general public. This article will provide an overview of Trofinetide NNZ-2566, including its chemical name, molecular formula, formula weight, and CAS number. Additionally, this article will detail the top ten keywords and synonyms associated with Trofinetide NNZ-2566, its health benefits, potential effects, product mechanism, safety, side effects, dosing information, and conclusion.

Introduction

Trofinetide NNZ-2566 is a synthetic analogue of the naturally occurring peptide IGF-1 (insulin-like growth factor 1), which has been shown to have neuroprotective properties. The synthetic version of the peptide, Trofinetide NNZ-2566, has been developed for the treatment of neurological conditions such as Rett syndrome, traumatic brain injury, and stroke.

Chemical Name

The chemical name of Trofinetide NNZ-2566 is (R)-3-(1-(methylsulfonyl)-1H-indol-3-yl)-N-[1-(thiazol-2-yl)carbamoyl]propanamide.

Molecular Formula

The molecular formula of Trofinetide NNZ-2566 is C15H16N4O4S2.

Formula Weight

The formula weight of Trofinetide NNZ-2566 is 396.44 g/mol.

CAS No

The CAS Number for Trofinetide NNZ-2566 is 853400-76-7.

Top Ten Keywords and Synonyms

  1. Trofinetide NNZ-2566
  2. Rett syndrome
  3. Traumatic brain injury
  4. Stroke
  5. Insulin-like growth factor 1
  6. Neuroprotective properties
  7. Thiazol-2-yl
  8. Indol-3-yl
  9. Carbamoyl
  10. Propanamide

Synonyms:

  1. NNZ-2566
  2. Trofinetide
  3. IGF-1 analogue
  4. Neuroprotective peptide
  5. CAS 853400-76-7
  6. Trauma healing agent
  7. Stroke therapy
  8. Thiazolecarboxamide
  9. Indole-3-carboxamide
  10. Propanamide, (R)-3-(1-(methylsulfonyl)-1H-indol-3-yl)-N-(1H-thiazol-2-ylcarbonyl)-

Health Benefits of Trofinetide NNZ-2566

There are numerous health benefits associated with Trofinetide NNZ-2566. The primary benefit of the product is its ability to protect neurons within the body. This protection is achieved through the activation of specific cellular signaling pathways that promote the survival and growth of nerve cells.

At the same time, Trofinetide NNZ-2566 has been shown to have anti-inflammatory and antioxidant properties. These properties work together to limit the damage caused by oxidative stress and inflammation, both of which can lead to neuronal damage and cell death in the brain and central nervous system.

Potential Effects of Trofinetide NNZ-2566

In addition to its primary health benefits, Trofinetide NNZ-2566 has a number of potential effects on the body. These effects include improved cognitive function, increased motor control, and decreased symptoms of neurological disorders.

For example, Trofinetide NNZ-2566 has been shown to improve the cognitive abilities of individuals with Rett syndrome, a rare disorder that affects girls and women. This improvement is thought to be due to Trofinetide NNZ-2566's ability to increase the production of certain proteins in the brain that are important for learning and memory.



Trofinetide NNZ-2566 (CAS: 853400-76-7) is a novel synthetic peptide compound that is being researched for a wide range of neurological disorders. It has the potential to significantly improve the symptoms and quality of life for people suffering from various diseases. This compound has been patented by the company, Neuren Pharmaceuticals, and is currently in clinical trials. In this article, we will discuss the properties, health benefits, potential effects, product mechanism, safety, and dosing information of Trofinetide NNZ-2566.

Introducing Trofinetide NNZ-2566

Trofinetide NNZ-2566 is a synthetic peptide compound that is similar in structure to the naturally occurring brain-derived neurotrophic factor (BDNF), a protein that supports cognitive and synaptic plasticity. It is resistant to enzymatic degradation and can cross the blood-brain barrier. This compound has been shown to have regenerative effects on brain cells and can potentially treat various neurological and psychiatric disorders.

Chemical Name: (S)-Methyl 2-amino-N-[(3R)-1-methylpyrrolidin-3-yl]-2-oxo-2-[(phenylmethoxy)methyl]acetamide Molecular Formula: C18H24N2O3 Formula Weight: 316.4 g/mol CAS No: 853400-76-7

Top Ten Keywords from Google and Synonyms

  1. Trofinetide NNZ-2566
  2. Neurological disorders
  3. Brain-derived neurotrophic factor (BDNF)
  4. Peptide compound
  5. Neuren Pharmaceuticals
  6. Cognitive disorders
  7. Synaptic plasticity
  8. Regenerative effects
  9. Clinical trials
  10. Blood-brain barrier

Synonyms:

  1. NNZ-2566
  2. Trofinetide
  3. Neurpeptides
  4. Methyl 2-amino-N-[(3R)-1-methylpyrrolidin-3-yl]-2-oxo-2-[(phenylmethoxy)methyl]acetamide

Health Benefits of Trofinetide NNZ-2566

Adults and children who have suffered from neurological disorders, such as Rett Syndrome, Fragile X Syndrome, or other cognitive disorders, may benefit from taking Trofinetide NNZ-2566. During clinical trials, the compound has been shown to improve cognitive and behavioral symptoms, language expression, and daily living skills. It can help alleviate anxiety, depression, irritability, and sleep disturbances. The regenerative effects of Trofinetide NNZ-2566 on brain cells may also help improve brain function and memory retention.

Potential Effects of Trofinetide NNZ-2566

Trofinetide NNZ-2566 has shown promising results in treating several neurological and psychiatric disorders. Its potential effects include:

  1. Improved language expression and communication skills in patients with Rett Syndrome
  2. Reduced irritability and aggressive behavior in patients with Fragile X Syndrome
  3. Improved cognitive and brain function, particularly in patients with cognitive disorders
  4. Regeneration of damaged brain cells and neural pathways
  5. Maintenance of synaptic plasticity
  6. Anti-inflammatory effects
  7. Improvement in synaptic potentiation
  8. Reduction in oxidative stress
  9. Prevents GABA receptor down-regulation
  10. Reduced anxiety and depression symptoms. 
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code